

International Partnership for
CRITICAL MARKERS OF DISEASE
CMOD

3rd Annual CMOD/Health Canada Biomarkers Meeting
May 24-25, 2011
Travelodge Conference Center
1376 Carling Ave
Ottawa, Ontario



Biomarkers and Emerging Sciences

Co-chairs:

Agnes Klein, Health Canada

Peter Libby, Harvard Medical School

Jean-Claude Tardif, Montreal Heart Institute

Updated information:

1. Due to construction, the meeting has been relocated to the Travelodge Conference Center, 1376 Carling Ave.
2. Doors open/breakfast available at 7:30 AM.
3. Complimentary breakfast, lunch and breaks are provided for all attendees.
4. For assistance at any time, please contact Vicki Price at vprice@trialynx.com or Therese Heinonen at [810-923-9108](tel:810-923-9108)/therese.heinonen@mhicc.org
5. Please notify the above if you need to cancel your registration as the meeting is sold out and there is an active wait list.

Agenda

May 24, 2011

SESSION 1 – 8:00 – 12:00

Introduction

Common threads linking major conditions

The Burden of Disease: Cardiology

The Burden of Disease: Neurology

The Burden of Disease: Oncology

The Burden of Disease: Diabetes

Roundtable Discussions

SESSION 2 – 1:00 – 5:00

The Personalized Medicine Landscape

Practical Challenges in Personalized Medicine - Genetics

Regulatory Oversight of Genetic Testing in Canada

Practical Challenges in Personalized Medicine – Molecular Imaging

Integrating Biomarkers and Emerging Sciences in Clinical Trials

Benefit-Risk Assessments

Roundtable Discussions

Jean-Claude Tardif, International Partnership CMOD

Peter Libby, Brigham and Women's Hospital

Peter Liu, University of Toronto

Sandra Black, Sunnybrook Health Sciences Center

Janet Dancey, Ontario Institute for Cancer Research

Lawrence Leiter, St. Michael's Hospital

Clarissa Desjardins, CEPMED

Tom Hudson, Ontario Institute for Cancer Research

Patrice Sarrazin, Health Canada

Anne Goodbody, Center for Probe Development

Jean-Claude Tardif, Montreal Heart Institute

Robyn Lim, Health Canada

May 25, 2011

SESSION 3 – 8:00 – 1:00 – CASE STUDIES SERIES

Marcie Glicksman – Harvard Neurodiscovery Center

Michael Phillips – Montreal Heart Institute

Robert Roberts – Ruddy Canadian Cardiovascular Genetics Centre

Philippe Bedard – Oncology, University of Toronto

Jill Davies – MedCan

Elizabeth Eisenhauer, Canadian Cancer Research Alliance

This meeting is sponsored by:

International Partnership for Critical Markers of Disease (CMOD)

Health Canada

Center of Excellence in Personalized Medicine (CEPMED)

Canadian Institute for Health Research (CIHR)

AstraZeneca Canada

Merck Frosst Canada

Pfizer Canada

Hoffmann La-Roche Canada

Eli Lilly Canada

Montreal Heart Institute Coordinating Center

Trialynx Inc.

Canadian Atherosclerosis Imaging Network (CAIN)

Co-Chairs and Faculty Members

CO-CHAIRS:

Agnes Klein, MD, Director, Center for Evaluation of Radiopharmaceuticals and Biotherapeutics, Health Canada

Jean-Claude Tardif, MD, Director, Research Center Montreal Heart Institute, Professor of Medicine, University of Montreal

Peter Libby, MD, Mallinckrodt Professor of Medicine, Harvard Medical School, Chief of Cardiovascular Medicine, Brigham & Women's Hospital

FACULTY:

Philippe Bedard, MD, FPCP, Assistant Professor, Department of Medicine, University of Toronto Medical Oncologist, Princess Margaret Hospital

Donald Black, MD, MBA, President, Trialynx Inc., Professor, National University of Ireland, Galway

Sandra Black, MD, FRCPC, Brill Chair in Neurology, University of Toronto, Sunnybrook Health Sciences Centre

Janet Dancey, MD, FRCPC, Program Director, High Impact Clinical Trials, Ontario Institute for Cancer Research, Director, Clinical Translational Research, NCIC Clinical Trials Group

Jill Davies, M.Sc, CCGC, Genetic Counselor, Program Director MedCan Clinic

Clarissa DesJardins, PhD, CEO CepMed Center of Excellence in Personalized Medicine

Elizabeth Eisenhauer, MD, FRPC, Director IND Program, Professor-Department of Oncology Queens University, Canadian Cancer Research Alliance

Marcie Glicksman, PhD, Co-Director Laboratory for Drug Discovery, Harvard Neurodiscovery Center, Partners Center for Drug Discovery, Assistant Professor, Neurology, Brigham and Women's Hospital

Anne Goodbody, PhD, Associate Executive Director & Director, Probe Validation & Regulatory Affairs

Therese Heinonen, DVM, Associate Director, Montreal Heart Institute Coordinating Center; Executive Director, International Partnership for Critical Markers of Disease

Thomas Hudson, MD, President and Scientific Director Ontario Institute for Cancer Research

Lawrence Leiter, MD, FRCPC, FACP, Division of Endocrinology and Metabolism St. Michael's Hospital

Robyn Lim, PhD, Scientific Advisor Office of Legislative and Regulatory Modernization Health Products and Food Branch, Health Canada

Peter Liu, MD, FRCPC, MSc, Scientific Director, Canadian Institutes of Health Research

Michael Phillips, PhD, Canada Research Chair in Translational Pharmacogenomics, Director, University of Montreal Pharmacogenics Centre, Associate Professor, University of Montreal

Robert Roberts, MD, FRCP (C) MACC President and CEO University of Ottawa Heart Institute, Professor of Medicine and Director, Ruddy Canadian Cardiovascular Genetics Centre

Patrice Sarrazin, PhD, Senior Scientific Evaluator In Vitro Diagnostics Devices, Medical Devices Bureau, Therapeutic Product Directorate, Health Canada